Latest Clinical Outcomes News

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.

Osteopore Limited has won tender bids to supply its innovative orthopaedic implants to two major public hospitals in Vietnam, marking a significant step in its Asia Pacific expansion.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.